Organogenesis Reports Positive Interim Analysis of Second Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/9/2026

1. TTAN
2. CHYM
3. BRZE
4. USO
5. KFY
6. EVMN
7. NOVN:SW
8. USB
9. DYN
10. NVS

Go back to Organogenesis Reports Positive Interim Analysis of Second Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis
(NASDAQ: ORGO) Delayed: 1.60 --0 (-0%)
Previous Close $1.60    52 Week High $ 
Open $1.60    52 Week Low $ 
Day High $1.60    P/E N/A 
Day Low $1.60    EPS $ 
Volume 100